Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Receivables (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Change in Receivables for 17 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 35.0% to -$2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.2 million, a 171.26% decrease, with the full-year FY2025 number at -$6.2 million, down 171.26% from a year prior.
  • Change in Receivables was -$2.6 million for Q4 2025 at Myriad Genetics, up from -$19.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $17.5 million in Q1 2023 to a low of -$19.0 million in Q3 2025.
  • A 5-year average of $1.7 million and a median of $50000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: plummeted 1120.0% in 2022, then skyrocketed 2600.0% in 2025.
  • Myriad Genetics' Change in Receivables stood at -$3.0 million in 2021, then rose by 16.67% to -$2.5 million in 2022, then surged by 52.0% to -$1.2 million in 2023, then crashed by 233.33% to -$4.0 million in 2024, then skyrocketed by 35.0% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Change in Receivables are -$2.6 million (Q4 2025), -$19.0 million (Q3 2025), and $16.2 million (Q2 2025).